Med-IQ CME Courses

In this brief 15-minute activity, you will:

– Follow the case of a patient who presents with foot drop and no other medical conditions
– Choose optimal management approaches by answering nongraded questions within the activity (answers are collected for informational purposes only and used to assess the effectiveness of this educational activity)
– See how your answers compare with those of your peers
– View video clips providing expert insights

This educational activity reviews emerging clinical evidence and evolving treatment strategies for transthyretin amyloid cardiomyopathy (ATTR-CM), with a focus on recently approved disease-modifying therapies. Learners will examine key clinical trial data related to efficacy, safety, quality of life, functional outcomes, and long-term disease stabilization, as well as explore how these findings may be applied in patient scenarios representative of contemporary clinical practice.

Meet a 52-year-old woman with type 2 diabetes and hypertension whose recent laboratory results reveal a decline in kidney function. How would you manage this patient? In this 15-minute activity, read about next steps in the management of advanced kidney disease.

Expert faculty dive into the rapidly evolving world of BCMA-directed bispecific antibodies for multiple myeloma, exploring practical strategies to bring these cutting-edge therapies into everyday clinical care.

This series was developed by Boston University Chobanian & Avedisian School of Medicine in collaboration with the American Academy of Physician Associates, the Association of PAs in Oncology, HealthTree Foundation, and Med-IQ.

In this CME activity, discover the latest information on investigational factor XI/XIa inhibitors, including results from completed clinical trials and news about ongoing clinical trials, to explore their potential role in managing stroke risk in patients with atrial fibrillation (AF).

In this #CME #MedX, get the latest guidance on managing hypertrophic cardiomyopathy (HCM), including confirming an obstructive HCM (oHCM) diagnosis, integrating recent clinical information on cardiac myosin inhibitor treatments, and addressing patients’ concerns and questions about living with HCM.

Faculty discusses the prevention and management of cytokine release syndrome (CRS), immune effector cell–associated neurotoxicity syndrome (ICANS), and infections in patients with relapsed/refractory multiple myeloma treated with BCMA-directed bispecific antibodies.

This series was developed by Boston University Chobanian & Avedisian School of Medicine in collaboration with the American Academy of Physician Associates, the Association of PAs in Oncology, HealthTree Foundation, and Med-IQ.

This webcast focuses on the role of wearable devices in the timely identification of atrial fibrillation (AF) and the evolving evidence around the rationale for and efficacy/safety of early rhythm control strategies, including guideline recommendations and expert insights on the use of antiarrhythmic drugs (AADs) and catheter ablation. It also incorporates an AI-powered patient simulator as a method by which participants can practice how they engage patients in shared decision-making discussions regarding rhythm control strategies

In this MedX activity, Robert Haddad, MD, explores the latest clinical data for emerging novel therapies for recurrent/metastatic head and neck squamous cell carcinoma with an emphasis on results presented at ESMO 2025.

Discover how communities of practice are expanding access to bispecific antibodies, as faculty share practical guidance on starting these therapies in community settings and smoothly transitioning patients from academic centers to local care.

This series was developed by Boston University Chobanian & Avedisian School of Medicine in collaboration with the American Academy of Physician Associates, the Association of PAs in Oncology, HealthTree Foundation, and Med-IQ.

This CME activity discusses the diagnosis and treatment of ATTR-CM and highlights key updates on ATTR-CM treatment presented at the HFSA Annual Scientific Meeting 2025 and AHA Scientific Sessions 2025.

In this 15-minute activity, meet 2 patients with arm pain, one of whom also presents with neck pain. How would you manage these patients? This accredited activity uses an interactive, quiz-driven microlearning format to explore clinical case scenarios with targeted questions, allowing clinicians to quickly assess their knowledge. Clinicians can compare their responses with those of their peers and receive expert guidance through video commentary.

This accredited activity reviews advancements in lung transplant surgery, with a focus on robotic lung transplant and ex vivo lung perfusion.

Patient advocate and HealthTree Foundation CEO Jenny Ahlstrom shares fresh survey insights into the physical, emotional, and social quality-of-life experiences of patients treated with bispecific antibodies, while spotlighting key educational, financial, and community resources designed to support them.

This series was developed by Boston University Chobanian & Avedisian School of Medicine in collaboration with the American Academy of Physician Associates, the Association of PAs in Oncology, HealthTree Foundation, and Med-IQ.

Empowering the Care Team: Practical Strategies for Implementing BCMA Therapies in Relapsed Refractory Multiple Myeloma

Through interactive cases and expert-led discussions, our ECHO® sessions and Community of Practice calls help community oncology teams:

• Characterize the safety and efficacy of BCMA-directed bsAbs for the treatment of MM
• Appropriately incorporate BCMA-directed bsAbs into cases of patients with MM that are representative of clinical practice
• Establish and follow workflows and lines of communication for monitoring and managing BCMA bsAb treatment-related adverse events
• Summarize the importance and benefits of CoPs to providing coordinated, multidisciplinary, and interprofessional care for patients with MM receiving BCMA-directed bsAbs

Hear from a panel of clinicians from community practices about their experiences, including the challenges and successes, with integrating B-cell maturation antigen (BCMA)-directed bispecific antibodies into their practices. Explore patient management strategies for bispecific antibodies, from starting treatment at a community center to providing long-term care after treatment initiation at either a community or tertiary center.

This CME activity reviews the efficacy and safety of available B-cell maturation antigen (BCMA)-directed bispecific antibodies for multiple myeloma and explores the latest clinical data on their use in earlier lines of therapy and in emerging combination regimens.

This CME activity reviews various barriers to accessing B-cell maturation antigen (BCMA)-directed therapies that patients with multiple myeloma may experience. The impact of these barriers on health outcomes is discussed, along with strategies and policy solutions to help overcome them.

This CME activity explores the latest clinical data and provides guidance on when to consider treatment with available B-cell maturation antigen (BCMA)-directed bispecific antibodies (BsAbs), chimeric antigen receptor (CAR) T-cell therapy, or antibody-drug conjugate (ADC) therapy for patients with relapsed/refractory multiple myeloma (RRMM) based on patient-, disease-, and treatment-related factors.

In this MedX activity, Michael Blaha, MD, explores the evolving landscape of low-density lipoprotein cholesterol (LDL-C) management in patients with atherosclerotic cardiovascular disease (ASCVD), with a focus on the current role of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and how emerging novel PCSK9 inhibitor formulations may be integrated into clinical practice as they become available.